D-0714-2026 Class II Ongoing

Recalled by McKesson — Irving, TX

FDA drug recall D-0714-2026 was initiated by McKesson on Jun 10, 2026 and is designated Class II. Reason for recall: Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment. The recall status is ongoing. Affected quantity: 74 units.

Recall details

Product Type
Drugs
Report Date
Jul 8, 2026
Initiation Date
Jun 10, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
74 units

Product description

Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01

Reason for recall

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

Distribution pattern

Nationwide within the United States

Code information

Lot #: CB0046, Exp. Date 06/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0714-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0714-2026. Report a data issue: hello@regdatalab.com.